Moore Capital Management LP Purchases New Stake in MBX Biosciences, Inc. $MBX

Moore Capital Management LP bought a new stake in MBX Biosciences, Inc. (NASDAQ:MBX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 64,893 shares of the company’s stock, valued at approximately $3,582,000.

Several other large investors have also recently added to or reduced their stakes in MBX. Russell Investments Group Ltd. grew its holdings in shares of MBX Biosciences by 4,131.4% during the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after purchasing an additional 1,446 shares during the last quarter. Strs Ohio lifted its holdings in MBX Biosciences by 128.6% in the first quarter. Strs Ohio now owns 1,600 shares of the company’s stock worth $48,000 after purchasing an additional 900 shares during the period. Royal Bank of Canada boosted its holdings in shares of MBX Biosciences by 59.6% in the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock valued at $49,000 after acquiring an additional 572 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of MBX Biosciences by 117.9% during the third quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock valued at $51,000 after acquiring an additional 1,567 shares during the period. Finally, California State Teachers Retirement System raised its holdings in MBX Biosciences by 64.7% during the fourth quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock worth $55,000 after purchasing an additional 689 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MBX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a research note on Friday, July 17th. UBS Group restated a “buy” rating and issued a $90.00 price objective on shares of MBX Biosciences in a report on Thursday, July 23rd. Wall Street Zen cut MBX Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Barclays reaffirmed an “overweight” rating and set a $88.00 target price on shares of MBX Biosciences in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $56.00 price target on shares of MBX Biosciences in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $77.00.

MBX Biosciences Stock Down 2.2%

Shares of NASDAQ MBX opened at $61.60 on Tuesday. MBX Biosciences, Inc. has a 12 month low of $9.63 and a 12 month high of $72.64. The company has a market cap of $2.97 billion, a price-to-earnings ratio of -25.56 and a beta of 0.09. The business has a fifty day simple moving average of $62.15 and a 200-day simple moving average of $43.21.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.10). As a group, sell-side analysts expect that MBX Biosciences, Inc. will post -3.11 EPS for the current fiscal year.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.